Guggenheim Securities updated their outlook on Immunovant (NASDAQ:IMVT) shares, raising the price target from $44.00 to $46.00 while maintaining a Buy rating on the stock. Currently trading at $23.23, ...

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Merck & Company (MRK – Research Report). The ...

Robert Kennedy Jr. will keep his share of any windfall from litigation against Merck (MRK) even if he becomes Donald Trump’s top U.S. health ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...

BB Biotech AG reports preliminary full-year 2024 results with a net profit of CHF 76 mn, proposing a dividend of CHF 1.80 per share at the AGM on March 19, 2025, focusing on shareholder returns and bi ...